Australia

Active Projects: 5

Project Investigator All Locations Start date End date
DFAT Vector Control Technical Landscape Analysis in the Indo-Pacific Allison J. Tatarsky, MPH China, Japan, Bangladesh, Bhutan, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Philippines, U.S. Virgin Islands, Oceania, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 Mandana Khalili, MD South Korea, Japan, India, Singapore, Belgium, Finland, France, Greece, Italy, Netherlands, Russia, United Kingdom, Mexico, Argentina, Brazil, Chile, Canada, Australia, New Zealand
Individual, social, and structural factors on disease transmission in marginalized populations Meghan Morris, PhD, MPH Tanzania, Namibia, Mexico, Jamaica, Australia
Communicable disease surveillance and prediction Simon D. Pollett, MBBS Australia
AIDS Malignancy Consortium (AMC) Lawrence Kaplan, MD Kenya, Malawi, Uganda, Tanzania, Zimbabwe, South Africa, India, Brazil, Australia

Archived Projects: 24

Project Investigator All Locations Start date End date
International AIDS Education and Training Center E. Michael Reyes, MD, MPH Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Gabon, Egypt, Morocco, Sudan, Tunisia, Botswana, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Ivory Coast, Gambia, Ghana, Guinea-Bissau, Mali, Niger, Nigeria, Senegal, Togo, Kyrgyzstan, China, Bangladesh, India, Iran, Nepal, Pakistan, Sri Lanka, Cambodia, Indonesia, Viet Nam, Laos, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Georgia, Iraq, Lebanon, Yemen, Czech Republic, Estonia, Greece, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Venezuela, Antigua and Barbuda, Bahamas, Barbados, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Puerto Rico, Trinidad and Tobago, Australia
Failure Time Methods for Family Disease Studies David Glidden, PhD United States, Australia
San Francisco National Clinical Trial Center, ESPIRIT Steven Deeks, MD Morocco, Japan, Singapore, Thailand, Israel, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, United Kingdom, Argentina, Brazil, Canada, Australia
WHO Adolescent HTC Review Update (PO# 200660799) George Rutherford, MD Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Western Africa, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, Japan, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka, Brunei, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus Mandana Khalili, MD Mexico, Argentina, Puerto Rico, Australia
Assess Clonidine and Aspirin in Noncardiac Surgery Patients at Risk of Perioperative Cardiovascular Event Rachel McKay, MD South Africa, China, India, Pakistan, Malaysia, Austria, Belgium, Denmark, France, Germany, Italy, Spain, Switzerland, United Kingdom, Argentina, Brazil, Chile, Colombia, Peru, Canada, Australia
Women, Children, and HIV Website Susan Coffey, MD Kenya, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Botswana, Lesotho, Namibia, South Africa, Swaziland, Gambia, Ghana, Liberia, Nigeria, India, Pakistan, Sri Lanka, Singapore, Philippines, United Kingdom, Anguilla, Antigua and Barbuda, Bahamas, Barbados, Cayman Islands, Dominica, Grenada, Jamaica, Saint Kitts and Nevis, Saint Lucia, Trinidad and Tobago, U.S. Virgin Islands, Northern Mariana Islands, Australia, Marshall Islands, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 Mandana Khalili, MD Egypt, Sweden, Mexico, Puerto Rico, Canada, Australia
Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Michelle Melisko, MD France, Germany, Ireland, Spain, Switzerland, United Kingdom, Canada, Australia
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV Anne Luetkemeyer, MD France, Germany, Italy, Russia, Spain, United Kingdom, Argentina, Puerto Rico, Canada, Australia
International Collaborative of Prospective Studies of HIV and Hepatitis in IDU Kimberly Page, PhD, MPH Netherlands, Canada, Australia
AIDS Malignancies Consortium Lawrence Kaplan, MD Kenya, Uganda, Zimbabwe, South Africa, India, Brazil, Australia
Office of the UN Special Envoy for Tuberculosis Eric Goosby, MD Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Central Asia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, South Korea, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Caribbean, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, United States, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu
Multicenter Uveitis Steroid Treatment (MUST) Trial Nisha Acharya, MD United Kingdom, Australia
International Collaborative of prospective studies of HIV and Hepatitis in IDU Stephen Shiboski, PhD Australia
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Ann Schwartz, PhD, MPH South Africa, India, Thailand, Belgium, Ireland, Italy, Spain, United Kingdom, Brazil, Peru, Australia
DARE: Delaney AIDS Research Enterprise to Find a Cure Steven Deeks, MD Sweden, Australia
Adolescents with Eating Disorders Project - The Baker Foundation Collaboration with the University of Melbourne Daniel Le Grange, PhD Australia
VIPS: Vascular Effects of Infection in Pediatric Stroke Heather Fullerton, MD China, Malaysia, Argentina, Chile, Australia
Fighting emerging antimalarial drug resistance Philip J. Rosenthal, MD Australia
Development of Antimalarial Drug Leads Through Inhibition of Food Vacuole Falcipains Philip J. Rosenthal, MD Australia
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial Nisha Acharya, MD India, Mexico, Australia
ENROLL-HD -A Prospective Registry Study in a Global Huntington's Disease Cohort Michael Geschwind, MD, PhD Argentina, Chile, Australia
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START Richard Price, MD Uganda, Morocco, South Africa, Mali, Nigeria, China, Japan, India, Malaysia, Thailand, Israel, Mexico, Brazil, Chile, Peru, Uruguay, Australia